Provided by Tiger Trade Technology Pte. Ltd.

Viking Therapeutics

30.89
+0.21000.68%
Post-market: 30.80-0.0900-0.29%19:59 EDT
Volume:1.22M
Turnover:37.49M
Market Cap:3.57B
PE:-7.43
High:30.92
Open:30.58
Low:30.29
Close:30.68
52wk High:43.15
52wk Low:22.96
Shares:115.55M
Float Shares:110.00M
Volume Ratio:0.58
T/O Rate:1.11%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.1600
EPS(LYR):-3.1920
ROE:-70.04%
ROA:-42.54%
PB:7.11
PE(LYR):-9.68

Loading ...

Should New Phase 2 Oral VK2735 Weight-Loss Data Require Action From Viking Therapeutics (VKTX) Investors?

Simply Wall St.
·
Yesterday

Viking Therapeutics to present at William Blair Growth Stock Conference

Reuters
·
May 21

How New Oral VK2735 Obesity Data At Viking Therapeutics (VKTX) Has Changed Its Investment Story

Simply Wall St.
·
May 15

Viking Therapeutics’ VK2735 demonstrates wieght loss in Phase 2 trial

TIPRANKS
·
May 12

Viking says oral VK2735 cuts weight up to 12.2% in Phase 2 trial

Reuters
·
May 12

BRIEF-Viking Therapeutics Presents Data From Its 13-Week Phase 2 Venture-Oral Dosing Trial

Reuters
·
May 12

Viking Therapeutics Presents Data From Its 13-Week Phase 2 Venture-Oral Dosing Trial of Vk2735 at European Congress on Obesity (Eco) 2026

THOMSON REUTERS
·
May 12

Viking Therapeutics presents Phase 2 oral VK2735 weight-loss data at ECO 2026

Reuters
·
May 05

Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (Eco) 2026

THOMSON REUTERS
·
May 05

Viking Therapeutics call volume above normal and directionally bullish

TIPRANKS
·
May 05

Viking Therapeutics Price Target Maintained With a $125.00/Share by BTIG

Dow Jones
·
May 04

Maxim Group Sticks to Its Buy Rating for Viking Therapeutics (VKTX)

TIPRANKS
·
May 01

Ligand Pharma Ends TR‑Beta License With Viking Therapeutics

TIPRANKS
·
May 01

Ligand, Viking dispute TR-Beta program termination under license agreement

Reuters
·
May 01

Viking Therapeutics Q1 Viewed as Supporting Maintenance Profile, Oppenheimer Says

MT Newswires Live
·
May 01

Viking Therapeutics price target lowered to $95 from $99 at Morgan Stanley

TIPRANKS
·
Apr 30

Viking Therapeutics Is Maintained at Overweight by Cantor Fitzgerald

Dow Jones
·
Apr 30

Chefs' Warehouse Inc : Morgan Stanley Raises Target Price to $83.00 From $76.00

THOMSON REUTERS
·
Apr 30

Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS) and Viking Therapeutics (VKTX)

TIPRANKS
·
Apr 30

Earnings Flash (VKTX) Viking Therapeutics Posts Q1 EPS -$1.37, vs. FactSet Est of -$0.98

MT Newswires Live
·
Apr 30